Literature DB >> 4038982

Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus.

E H Cole, J Schulman, M Urowitz, E Keystone, C Williams, G A Levy.   

Abstract

Monocyte infiltration and activation of the coagulation system have been implicated in the pathophysiology of glomerulonephritis. In this study, spontaneous procoagulant activity (PCA) was measured in circulating mononuclear cells to determine whether elevated PCA correlated with the presence of proliferative glomerulonephritis in patients with systemic lupus erythematosus (SLE). No increase in PCA was found in 20 patients with end-stage renal failure, 8 patients with glomerulonephritis without SLE, and 10 patients undergoing abdominal surgical or orthopedic procedures as compared with 20 normal controls. In eight patients with SLE but with no apparent active renal disease, PCA was not elevated above normal basal levels. Seven additional patients with SLE who had only mesangial proliferation on biopsy also had no increase in PCA. In contrast, eight patients with focal or diffuse proliferative lupus nephritis, and one patient with membranous nephritis who ultimately developed a proliferative lesion, had a marked increase in PCA with greater than 100 times the base-line levels. The activity was shown to originate in the monocyte fraction of the mononuclear cells and was shown to be capable of cleaving prothrombin directly. The prothrombinase activity was not Factor Xa, because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of Factor Xa inhibitors. Monocyte plasminogen activator determinations did not correlate with renal disease activity. We conclude that monocyte procoagulant activity, a direct prothrombinase, seems to correlate with endocapillary proliferation in lupus nephritis and could be a mediator of tissue injury.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038982      PMCID: PMC423616          DOI: 10.1172/JCI111784

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

Authors:  E J BOWIE; J H THOMPSON; C A PASCUZZI; C A OWEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis.

Authors:  N M Thomson; I J Simpson; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-02       Impact factor: 4.330

3.  Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.

Authors:  H Rothberger; T S Zimmerman; H L Spiegelberg; J H Vaughan
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

4.  Lupus nephropathy without clinical renal involvement.

Authors:  S K Mahajan; N G Ordóñez; P J Feitelson; V S Lim; B H Spargo; A I Katz
Journal:  Medicine (Baltimore)       Date:  1977-11       Impact factor: 1.889

5.  Tissue factor activity of normal and leukemic cells.

Authors:  S K Garg; J Niemetz
Journal:  Blood       Date:  1973-11       Impact factor: 22.113

6.  The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function.

Authors:  P Kincaid-Smith
Journal:  Med J Aust       Date:  1972-09-09       Impact factor: 7.738

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Lupus nephritis. Clinical course as related to morphologic forms and their transitions.

Authors:  D S Baldwin; M C Gluck; J Lowenstein; G R Gallo
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

9.  Renal damage in systemic lupus erythematosus with normal renal function.

Authors:  R M Hollcraft; E L Dubois; G D Lundberg; S B Chandor; S B Gilbert; F P Quismorio; B H Barbour; G J Friou
Journal:  J Rheumatol       Date:  1976-09       Impact factor: 4.666

10.  Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A.

Authors:  F R Rickles; J A Hardin; F A Pitlick; L W Hoyer; M E Conrad
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

View more
  6 in total

1.  Glomerular procoagulant activity in human proliferative glomerulonephritis.

Authors:  P G Tipping; J P Dowling; S R Holdsworth
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

2.  The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis.

Authors:  K Yamamoto; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Expression of macrophage procoagulant activity in murine systemic lupus erythematosus.

Authors:  E H Cole; J Sweet; G A Levy
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection.

Authors:  M Abecassis; J A Falk; L Makowka; V J Dindzans; R E Falk; G A Levy
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

Review 5.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

6.  Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation.

Authors:  M P McGee; S Foster; X Wang
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.